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Background:  Little  is  known  about  depressive  symptoms  in  heart failure  with  preserved  ejection  fraction
(HFpEF,  EF  ≥50%).  We  aimed  to assess  the  prevalence  of  depression,  to clarify  the  impact  of  depressive
symptoms  upon  clinical  outcomes,  and  to identify  factors  associated  with  these  symptoms  in HF  with
reduced  EF  (HFrEF,  EF <50%)  and  HFpEF.
Methods  and  results:  A total  of  106  HF outpatients  were  enrolled.  Of  them,  61 (58%)  had  HFpEF.  Most
patients  were  male  (HFrEF  80%,  HFpEF  70%)  and  the  mean  of plasma  B-type  natriuretic  peptide  (BNP)
level  in  the  HFrEF  group  was similar  to  that  in  the  HFpEF  group  (164.8  ± 232.8  vs.  98.7  ± 94.8 pg/mL).  HFrEF
patients  were  treated  more  frequently  with  beta-blockers  compared  with  HFpEF  patients  (71% vs.  43%,
p  = 0.004).  Depressive  symptoms  were  assessed  using  the  Center  for  Epidemiologic  Studies  Depression
Scale  (CES-D).  The  prevalence  of  depression  (CES-D  score ≥16),  and  CES-D  score  did  not  signiﬁcantly  differ
between  HFrEF  and  HFpEF  (24%  vs. 25%, 14.1 ±  8.3  vs.  12.1  ±  8.3, respectively).  During  the  2-year  follow-
up,  depressed  patients  had  more  cardiac  death  or  HF hospitalization  in  HFrEF  (55%  vs. 12%,  p = 0.002)
and  HFpEF  (35%  vs. 11%,  p =  0.031).  Cox proportional  hazard  analysis  revealed  that  a  higher  CES-D  score,
indicating  increased  depressive  symptoms,  predicted  cardiac  events  independent  of BNP  in HFrEF  [hazard
ratio (HR)  1.07,  95%  conﬁdence  interval  (CI)  1.01–1.13]  and  HFpEF  (HR 1.09,  95%CI 1.04–1.15).  Multiple
regression  analyses  adjusted  for BNP  showed  that  independent  predictors  of  depressive  symptoms  were
non-usage  of beta-blockers  and  being  widowed  or  divorced  in  HFrEF.  On  the  other  hand,  usage  of  warfarin
was the  only  independent  risk  factor  for depressive  symptoms  in  HFpEF  (all,  p <  0.05).
Conclusions:  Depressive  symptoms  are  common  and  independently  predict  adverse  events  in
HFrEF/HFpEF  patients.  This study  suggests  that  beta-blockers  reduce  depressive  symptoms  in HFrEF.
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Heart failure (HF) imposes one of the highest disease burdens
ompared to any medical condition in Japan, with an estimated
.3 million outpatients experiencing HF in 2030 [1].  The risk for
eveloping HF increases with advancing age, and HF is one of the
ost frequent causes of hospitalization [2].
HF has been traditionally classiﬁed with systolic and diastolic
F, although these should not be considered as separate entities,
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oi:10.1016/j.jjcc.2012.01.010ession  remains  to  be elucidated  in  HFpEF.
anese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.
as most HF patients have both systolic and diastolic dysfunction at
rest or with exercise. Diastolic HF has also been described as HF
with preserved ejection fraction (HFpEF). The prevalence of HFpEF
has increased over time compared to HF with reduced EF (HFrEF)
[3]. Such changes may  be due to the demographic shift caused
by the aging population, and the evolution of more sophisticated
therapeutic strategies for HF. Patient characteristics differ between
HFrEF and HFpEF groups. Those affected by the latter have been
older and more often women, and are more likely to have underly-
ing hypertension [3–5]. Despite these differences, the prognosis of
HFpEF has been shown to be poor, with outcomes similar to those
for HFrEF in Japan as well as Western countries [3,4].
Depressive disorder is a common healthcare problem in HF.
The prevalence rate of clinically signiﬁcant depression among
HF patients was 21.5% in a meta-analysis of 27 studies, and the
vier Ltd. All rights reserved.
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revalence rates reported across these studies ranged from 9% to
0% [6].  Studies including our own have shown that symptoms
f depression are independent risk factors for adverse clinical
utcomes among HF patients [7–10]. However, most of these
tudies targeted HF patients with systolic dysfunction. The preva-
ence of depression and its effect on clinical outcomes in HFpEF
emains to be fully elucidated. Given the increases in HFpEF and
ts poor prognosis, depressive symptoms in HFpEF should receive
mmediate attention.
Several clinical trials have investigated the effects of depres-
ion treatment in patients with cardiovascular disease including
F [11,12]; however, these studies failed to ﬁnd concrete evidence.
onsidering the pathophysiological differences between HFrEF and
FpEF and the fact that established therapy for HFrEF does not
ecessarily provide beneﬁcial effects in HFpEF patients [13], the
reatment strategy for depression may  also differ between HFrEF
nd HFpEF. Identifying factors contributing to depressive symp-
oms could help health professionals to determine the optimal
edical approach for reducing depressive symptoms, and thereby
mprove clinical outcomes among HFrEF and HFpEF patients.
Therefore, the purpose of this study was (1) to assess the
revalence of depression, (2) to clarify the impact of depressive
ymptoms upon clinical outcomes, and (3) to identify factors asso-
iated with these symptoms in HFrEF and HFpEF patients.
ethods
atients and study design
This study was a prospective, observational study of HF out-
atients. The institutional review board of University of Tokyo
pproved this study (No. 1445 and 1445-1). All participants pro-
ided informed consent. The details of the study design have
een described previously [9,14].  All consecutive HF outpatients
ho were making scheduled visits to the cardiovascular outpa-
ient clinic of the University Hospital in Tokyo between July 2006
nd November 2006 were enrolled. The attending physician deter-
ined whether each patient met  our criteria based on medical
ecords and the patient symptoms.
Patients were included when they were diagnosed with HF in
ccordance with Framingham HF criteria [15] and were at least
0 years of age. Exclusion criteria were the physical inability to
omplete the questionnaire, or inability or unwillingness to give
nformed consent. We  excluded HF patients with etiology of valvu-
ar heart diseases in cases where they had not been hospitalized
ue to worsening of HF as well as cases where the current severity
f valvular heart disease was trivial or mild. We  also excluded two
atients receiving hemodialysis, because we considered that the
umber of hemodialysis patients in the study was not enough to
valuate impacts of hemodialysis on depressive symptoms, given
he fact that hemodialysis may  be closely associated with other
linical and psychological status [16].
In this study, patients with left ventricular EF (LVEF) of ≥50%
ere classiﬁed as having HFpEF, whereas those with LVEF of <50%
ere classiﬁed as having HFrEF [3].  LVEF was assessed using ultra-
ound cardiography.
Patients were followed up for a median period of 2.1 years, and
hey received usual care from their primary care physicians and/or
ardiologists.
ndpointsThe primary endpoint was the composite endpoint of cardiac
eath or hospitalization due to worsening of HF. Hospitalization for
F was deﬁned as an admission primarily diagnosed with HF. Theiology 60 (2012) 23–30
information on endpoints was collected from medical records. We
also mailed a follow-up letter to all patients or their family approx-
imately 2 years after the initial assessment to enquire about the
patients’ clinical outcomes. If the requested information was not
received within 4–6 weeks after mailing, we  asked the attending
physicians about the clinical outcomes.
Depressive symptoms
Depressive symptoms were measured using the Japanese ver-
sion of the Center for Epidemiologic Studies Depression Scale
(CES-D) [17,18].  CES-D is a 20-item self-report questionnaire
designed for the screening of depressive symptoms on a four-
point Likert scale ranging from 0 to 3. The scores for each item are
summed to give a range of total scores from 0 to 60. A higher score
indicates a greater tendency toward depressive symptoms. A total
score of ≥16 indicates the presence of clinically signiﬁcant depres-
sion, and thus we  classiﬁed patients with scores of ≥16 as suffering
from depression. CES-D has previously been used in patients with
HF [6,19].  Semantic equivalence of the Japanese version of CES-D
with the original English version has been ascertained by means
of back translation. Validity and reliability of CES-D Japanese ver-
sion have also been conﬁrmed as described previously [9,18].  In the
Japanese version, the cut-off value of 16 was  also optimal [9,18].
Measures
The following clinical information was  collected from med-
ical records at baseline: etiology of HF; duration of HF; prior
hospitalizations for HF; New York Heart Association (NYHA) func-
tional class; B-type natriuretic peptide (BNP); LV end-diastolic
diameter by ultrasound cardiography; systolic/diastolic blood
pressure; heart rate; atrial ﬁbrillation including paroxysmal
atrial ﬁbrillation; hemoglobin concentration; estimated glomeru-
lar ﬁltration rate (GFR) (calculated using the Japanese formula
[20], i.e. estimated GFR = 194 × age−0.287 × creatinine−1.094 [and, if
female, ×0.739]); diabetes mellitus; and medication including -
blockers, angiotensin-converting enzyme inhibitors (ACEIs), and/or
angiotensin II receptor blockers (ARBs), warfarin, and antidepres-
sants and/or anti-anxiety drugs.
We  asked patients to complete a self-administered question-
naire to assess demographic and clinical characteristics. This
questionnaire included gender, age, marital status, educational
level, employment, living situation, and CES-D.
Statistical analysis
Categorical data are presented as frequencies and percentages.
For continuous variables with a normal distribution, the mean and
standard deviations are reported. For variables not normally dis-
tributed, the median and inter-quartile ranges (IQR) are reported.
Kaplan–Meier curves were developed to examine the unadjusted
relationship of depression with the endpoints, using the log-rank
test for statistical comparison. Cox proportional hazard models
were used to assess the relationship between depressive symptoms
and the endpoints after adjustment for log BNP. The logarithmic
BNP was included in the model by forced entry, as a measure to
assess the severity of HF.
To identify variables related to depressive symptoms, a uni-
variate analysis was  initially performed. The dependent variable
was the CES-D score, and independent variables were demo-
graphic and clinical characteristics. Pearson’s product–moment
correlation coefﬁcient or Spearman’s rank-correlation coefﬁcient
was calculated for continuous variables. The Student t-test or the
Mann–Whitney U-test was  used to evaluate differences between
the two groups. One-way analysis of variance was also used to
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ompare the score between the three groups. After assessing the
ulticollinearity, a multiple regression analysis with adjustment
or logarithmic BNP was conducted. Variables that were related to
epressive symptoms at p < 0.10 in the univariate analysis were
ntered into the model. They were then selected using the back-
ard method (the signiﬁcance level required for retention in the
odel was 0.20).
All statistical tests were two-tailed, and statistical signiﬁcance
as deﬁned as p < 0.05. All analyses were performed with SAS ver-
ion 9.2 for Windows (SAS Institute Inc., Cary, NC, USA).
esultsaseline characteristics
A total of 115 patients participated in the survey. Nine patients
ere excluded for the following reasons: 2 patients did not return
able 1
aseline characteristics of study patients.
HF with reduced EF (N
Depressive symptoms
The CES-D score ≥16 11(24%) 
The  CES-D score 14.1 ± 8.3 
Demographic characteristics
Gender, male 36(80%) 
Age,  years 61.1 ± 16.4 
Marital status
unmarried 6(13%) 
married 33(73%) 
divorced or widowed 6(13%) 
Education, >12 years 19(42%) 
Employment, employed 19(42%) 
Living-alone 5(11%) 
Current smoker 9(20%) 
Clinical characteristics
Etiology of HF
Ischemic 17(38%) 
Cardiomyopathy 19(42%) 
Valvular heart disease 2(4.4%) 
Hypertension 2(4.4%) 
Congenital heart disease 5(11%) 
Others or unknown 0(0%) 
Duration of HF, years 1.7 (0.9–3.9) 
Prior  hospitalization for HF 30(67%) 
NYHA functional class 
I  8(18%) 
II  29(64%) 
III  8(18%) 
BNP, pg/mL 164.8 ± 232.8 
Median (IQR) 65.0(35.3–187.3) 
LVEF, % 38.7 ± 8.1 
LVDd, mm 59.6 ± 6.8 
Systolic BP, mmHg 123.2 ± 22.8 
Diastolic BP, mmHg  71.6 ± 13.5 
Heart  rate, beats/min 72.1 ± 12.6 
Atrial  ﬁbrillation 
Persistent 11(24%) 
Paroxysmal 2(4.4%) 
Hemoglobin, g/dL 13.4 ± 2.5 
Estimated GFR, mL/min/1.73 m2 60.4 ± 24.3 
Estimated GFR<60 24(53%) 
Diabetes mellitus 17(38%) 
Medication
-Blockers 32(71%) 
ACEIs and/or ARBs 33(73%) 
Digoxins 14(31%) 
Diuretics 36(80%) 
Warfarin 16(36%) 
Antidepressants and/or Anti-anxiety drugs 5(11%) 
F, heart failure; EF, ejection fraction; NYHA, New York Heart Association; BNP, B-type na
iastolic diameter; BP, blood pressure; GFR, glomerular ﬁltration rate; ACEIs, angiotensin
ymptoms were assessed with the Center for Epidemiologic Studies Depression Scale (C
ES-D  score of 16 or greater was  considered those with depression. Values are n (%), meaiology 60 (2012) 23–30 25
the questionnaire, more than 80% of all items were missing in the
questionnaire of 6 patients, and the medical data of 1 patient were
not available at baseline. Thus, 106 patients were included in the
ﬁnal analysis. The effective response rate was 92.2%. Characteristics
of patients were not different between study patients and those not
included in the study.
Demographic and clinical characteristics of the study patients
are shown in Table 1. Fifty-eight percent of study patients had
HFpEF. The mean age at baseline was 61 years in the HFrEF group
and 67 years in the HFpEF group. Most patients were male (HFrEF
80%, HFpEF 70%) and married (HFrEF 73%, HFpEF 70%). The median
of plasma BNP level in the HFrEF group was similar to that in the
HFpEF group (65 pg/mL vs. 71 pg/mL, respectively). The prevalence
rate of atrial ﬁbrillation did not signiﬁcantly differ between HFrEF
and HFpEF groups (29% vs. 36%, respectively). HFrEF patients were
treated more frequently with -blockers compared with HFpEF
patients (71% vs. 43%, respectively; p = 0.004). Among those who
 = 45) HF with preserved EF (N = 61) p-Value
15(25%) 0.986
12.8 ± 8.3 0.439
43(70%) 0.267
66.5 ± 15.4 0.084
10(16%) 0.909
43(70%)
8(13%)
28(46%) 0.706
28(46%) 0.706
8(13%) 0.756
5(8%) 0.076
0.015
17(28%)
13(21%)
13(21%)
6(9.8%)
8(13%)
4(6.6%)
3.5(1.6–6.5) 0.050
25(41%) 0.009
0.288
19(31%)
32(52%)
10(16%)
98.7 ± 94.8 0.406
70.9(29.0–134.5)
60.9 ± 7.4 <0.001
49.9 ± 6.6 <0.001
126.3 ± 20.1 0.469
70.5 ± 10.2 0.656
70.3 ± 12.5 0.481
0.541
16(26%)
6(9.8%)
13.0 ± 2.0 0.299
61.5 ± 18.8 0.806
31(51%) 0.798
20(33%) 0.594
26(43%) 0.004
39(64%) 0.306
16(26%) 0.581
35(57%) 0.014
30(49%) 0.162
2(3.3%) 0.132
triuretic peptide; LVEF, left ventricular ejection fraction; LVDd, left ventricular end-
-converting-enzyme inhibitors; ARBs, angiotensin II receptor blockers. Depression
ES-D), a higher score represents having more depressive symptoms. Patients with
n ± standard deviation, or median (inter-quartile range).
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ardiac  events represent cardiac death or hospitalization for heart failure. HF, hear
ere taking -blockers, carvedilol was prescribed to 97% in HFrEF
nd 81% in HFpEF.
Overall, 11 (24%) HFrEF patients and 15 (25%) HFpEF patients
cored ≥16 on CES-D and thus were classiﬁed as depressed. There
as no signiﬁcant difference in the CES-D score between HFrEF
nd HFpEF groups (14.1 ± 8.3 vs. 12.8 ± 8.3, respectively). Five (11%)
FrEF patients and 2 (3.3%) HFpEF patients were taking antidepres-
ants and/or anti-anxiety drugs.
he relationship of depressive symptoms with adverse clinical
utcomes
Of 106 patients, vital status data were available in 105 patients.
he median days of follow-up was 756 (2.1 years; IQR, 732–738).
uring the follow-up period, 10 (22%) patients in HFrEF and 10
17%) patients in HFpEF either died from cardiac cause or were
ospitalized for HF at least once. The cumulative 1- and 2-year com-
osite endpoint rates were 18% and 22% in HFrEF, and 14% and 17%
n HFpEF, respectively.
Compared with non-depressed patients, depressed patients
eﬁned as having a CES-D score of ≥16 had higher rates of cardiac
eath or HF hospitalization, not only for those with HFrEF [12% vs.
5%, p = 0.002; hazard ratio (HR) 5.87; 95% conﬁdence interval (CI)
.65–20.9, p = 0.006; Fig. 1A], but also for those with HFpEF (11% vs.
5%; p = 0.031; HR 3.60, 95% CI 1.04–12.5, p = 0.043; Fig. 1B). Table 2
hows the results of Cox proportional hazard analysis. A higher CES-
 score, indicating increased depressive symptoms, was  strongly
ssociated with an increased risk of the composite endpoint in
FrEF (HR 1.07; 95% CI 1.01–1.13; p = 0.023; HR for each 1-point
hange in total score on the CES-D scale) and HFpEF (HR 1.09; 95%CI
.04–1.15; p = 0.001) groups. After adjustment of the log BNP value,
able 2
elationship of depressive symptoms with adverse clinical outcomes.
HF with reduced EF (N = 45) 
HR (95% CI) 
Cardiac death or hospitalization for HF
Unadjusted 1.07 (1.01–1.13) 
Adjusted for BNP level 1.08 (1.01–1.15) 
All-cause mortality
Unadjusted 1.14 (1.06–1.23) 
Adjusted for BNP level 1.25 (1.08–1.45) 
F, heart failure; EF, ejection fraction; HR, hazard ratio; CI, conﬁdence interval; BNP, B-
pidemiologic Studies Depression Scale (CES-D), a higher score represents more having dﬁned as Center for Epidemiologic Studies Depression Scale (CES-D) score of ≥16.
e; EF, ejection fraction.
depressive symptoms were still associated with adverse cardiac
events, irrespective of LVEF (p = 0.033 in HFrEF, p = 0.013 in HFpEF;
Table 2).
The 1-and 2-year mortality rates were 6.7% and 11.3% in HFrEF
patients and 3.6% and 9.0% in HFpEF patients, respectively. None
of the patients died from suicide. A Kaplan–Meier survival anal-
ysis showed that mortality from any cause in depressed patients
was greater than that for non-depressed patients with HFrEF (48%
vs. 0%; p < 0.001). Whereas mortality was not signiﬁcantly different
between patients with and without depression in HFpEF (15% vs.
11%; p = 0.547). As shown in Table 2, a higher CES-D score was  signif-
icantly associated with an increased risk of mortality in the HFpEF
group (HR 1.08; 95% CI 1.01–1.15; p = 0.025) as well as in the HFrEF
group (HR 1.14; 95% CI 1.06–1.23; p < 0.001). Depressive symptoms
remained predictive of mortality after adjustment of BNP levels in
the HFrEF group (p = 0.002).
Factors associated with depressive symptoms
Table 3 compares the CES-D score between the two or three pop-
ulations stratiﬁed by various patient characteristics. In the HFrEF
group, living alone and marital status were predictive of depressive
symptoms. Tukey’s multiple comparisons found that patients who
were widowed or divorced experienced signiﬁcantly more depres-
sive symptoms than HFrEF patients who were married (p < 0.05).
Non-usage of -blockers as well as ACEIs and/or ARBs was also
associated with having more depressive symptoms in the HFrEF
group (all, p < 0.05). As for HFpEF, there was a signiﬁcant positive
relationship between the log BNP level and depressive symptoms.
HFpEF patients who  had persistent atrial ﬁbrillation experienced
more depressive symptoms than patients who  did not have atrial
HF with preserved EF (N = 60)
p-Value HR (95% CI) p-Value
0.023 1.09 (1.04–1.15) 0.001
0.033 1.08 (1.02–1.14) 0.013
<0.001 1.08 (1.01–1.15) 0.025
0.002 1.07 (0.994–1.16) 0.070
type natriuretic peptide. Depressive symptoms were assessed with the Center for
epressive symptoms.
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Table  3
Univariate predictors of depressive symptoms.
HF with reduced EF
(N = 45)
p-Value HF with preserved EF
(N = 61)
p-Value
Gender Female 18.0 ± 10.1 0.111 13.8 ± 9.2 0.535
Male 13.1 ± 7.6 12.4 ± 8.0
Age,  years 0.276 0.066 0.074 0.573
Marital status Unmarried 13.3 ± 5.9 0.011 8.8 ± 4.5 0.107*
Married 12.5 ± 7.0 14.2 ± 9.0
Divorced or widowed 23.2 ± 11.8 10.1 ± 5.6
Education >12  years 13.1 ± 8.9 0.488 12.6 ± 8.8 0.867
≤12  years 14.8 ± 7.8 13.0 ± 8.0
Employment Employed 12.3 ± 8.6 0.229 12.2 ± 7.2 0.614
Unemployed 15.3 ± 8.0 13.3 ± 9.2
Living-alone Yes  21.4 ± 12.1 0.034 9.8 ± 4.0 0.072
No  13.2 ± 7.4 13.3 ± 8.7
Current smoker Yes 13.9 ± 4.7 0.919 11.6 ± 5.4 0.738
No  14.1 ± 9.0 12.9 ± 8.5
Ischemic etiology of HF Yes 14.6 ± 8.7 0.718 13.1 ± 6.3 0.856
No  13.7 ± 8.2 12.7 ± 9.0
Duration of HF, years 0.045 0.767 −0.083 0.526
Prior  hospitalization for HF Yes 13.3 ± 8.4 0.406 12.8 ± 9.6 0.998
No 15.5  ± 8.0 12.8 ± 7.4
NYHA  functional class I 12.4 ± 2.0 0.758 10.8 ± 4.8 0.159
II  14.1 ± 9.7 12.7 ± 8.7
III  15.5 ± 6.3 17.0 ± 11.1
Log  BNP, pg/mL 0.239 0.115 0.338 0.008
LVEF,  % −0.156 0.308 0.031 0.811
LVDd,  mm 0.197 0.199 −0.218 0.094
Systolic BP, par 10 mmHg 0.218 0.151 −0.212 0.102
Diastolic BP, par 10 mmHg  0.151 0.323 −0.133 0.308
Heart  rate, beats/min 0.014 0.927 0.061 0.638
Atrial  ﬁbrillation
Persistent Yes 15.7 ± 9.6 0.552 17.7 ± 12.2 0.006*
Paroxysmal Yes 9.0 ± 9.9 15.7 ± 2.7
No  13.8 ± 7.8 10.4 ± 5.6
Hemoglobin, g/dL −0.194 0.203 −0.028 0.831
Estimated GFR ≥60 13.2 ± 8.9 0.535 11.6 ± 8.3 0.255
mL/min/1.73 m2 <60 14.8 ± 7.7 14.0 ± 8.3
Diabetes mellitus Yes 15.8 ± 9.0 0.271 11.0 ± 6.0 0.177
No  13.0 ± 7.7 13.7 ± 9.1
Medication
-blockers Yes  12.3 ± 7.1 0.021 11.9 ± 7.1 0.460
No  18.5 ± 9.5 13.5 ± 9.1
ACEIs  and/or ARBs Yes 12.6 ± 7.6 0.043 13.3 ± 9.2 0.532
No  18.2 ± 8.9 11.9 ± 6.4
Digoxins Yes 16.4 ± 9.7 0.215 13.1 ± 12.9 0.918
No  13.0 ± 7.4 12.7 ± 6.1
Diuretics Yes  14.6 ± 9.0 0.185 12.7 ± 8.7 0.899
No  11.9 ± 4.0 13.0 ± 7.9
Warfarin Yes  14.9 ± 9.4 0.632 15.2 ± 9.6 0.027
No  13.6 ± 7.7 10.5 ± 6.1
Antidepressants Yes 23.4 ± 12.9 0.144 22.0 ± 4.2 0.111
and/or Anti anxiety drugs No 12.9 ± 6.9 12.5 ± 8.2
HF, heart failure; EF, ejection fraction; NYHA, New York Heart Association; BNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction; LVDd, left ventricular end-
diastolic diameter; BP, blood pressure; GFR, glomerular ﬁltration rate; ACEIs, angiotensin-converting-enzyme inhibitors; ARBs, angiotensin II receptor blockers. Depression
symptoms were assessed with the Center for Epidemiologic Studies Depression Scale (CES-D), a higher score represents having more depressive symptoms. Patients with
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uES-D  score of 16 or greater was  considered those with depression. Values are mean
ank-correlation coefﬁcient.
* p < 0.05 by the Tukey’s multiple comparisons: married vs. divorced or widowed
brillation after analysis with Tukey’s multiple comparison
p < 0.05). Usage of warfarin was also predictive of depressive
ymptoms in HFpEF. On the other hand, usage of -blockers as
ell as ACEIs and/or ARBs was not related to depressive symptoms
n HFpEF.
Table 4 shows the results of the multiple regression analy-
is adjusted for log BNP level. Because there was  a signiﬁcant
elationship between marital status and living alone (p < 0.001),
e used the variables of marital status instead of living alone in
ultivariate analyses. Independent predictors of more depressiveymptoms were non-usage of -blockers and being widowed or
ivorced in HFrEF patients (standard partial regression coefﬁcients
s] = −0.301, p = 0.030; s = 0.425, p = 0.003, respectively) and
sage of warfarin in HFpEF patients (s = 0.253, p = 0.038).ndard deviation, Pearson’s product–moment correlation coefﬁcient, or Spearman’s
resence of atrial ﬁbrillation vs. persistent atrial ﬁbrillation.
Discussion
We  found that depression was common (24% in the HFrEF group
and 25% in the HFpEF group) and the prevalence did not differ
among the two groups experiencing different systolic functions.
To our knowledge, this is the ﬁrst Japanese study to demonstrate
that an increase in depressive symptoms is associated with adverse
cardiac events independently of HF severity, not only in those
with HFrEF but also in those with HFpEF. An exploratory analy-
sis designed for a better understanding of depressive symptoms
showed that the independent risk factors for depressive symptoms
were non-usage of -blockers and being widowed or divorced in
the HFrEF group, and usage of warfarin in the HFpEF group. These
ﬁndings highlight the need for screening depressive symptoms
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Table 4
Multivariate modeling of depressive symptoms.
Parameter estimate s p-Value
HF with reduced EF (N = 45)
Usage of -blockers −5.43 −0.301 0.030
Married status
Divorced or widowed vs. married 10.22 0.425 0.003
Unmarried vs. married 2.81 0.117 0.408
R2 (Adjusted R2) 0.323 (0.255)
HF  with preserved EF (N = 60)
Usage of warfarin 4.19 0.253 0.038
LVDd,  mm −0.23 −0.182 0.131
R2 (Adjusted R2) 0.220 (0.178)
HF, heart failure; EF, ejection fraction; s, standard partial regression coefﬁcients; LVDd, left ventricular end-diastolic diameter. Depressive symptoms were assessed with
the  Center for Epidemiologic Studies Depression Scale (CES-D), a higher score represents more having depressive symptoms. Log BNP level was entered into the multivariate
model  forcedly. After we assessed the multicollinearity, variables that were related to the depressive symptoms at p < 0.10 in univariate analysis (Table 3) were entered into
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che  model. Then the variables were selected by backward methods (p < 0.20).
mong HF patients irrespective of LVEF and suggest that HF treat-
ent strategies for depressive symptoms may  differ according to
ystolic function.
revalence of depression
The prevalence of depression among those with HFpEF has
ot yet been determined in a deﬁnitive manner for this disorder.
ur study revealed that about a quarter of patients had depres-
ion deﬁned as having a CES-D score of ≥16 in the HFpEF group
s well as in the HFrEF group. This prevalence rate is similar to
he results obtained from a meta-analysis in HF [6],  and is 2–3
imes higher compared with that in the general population [21].
ecause the relationship between depression and HF is based on
 complex pathophysiology, it is still unclear whether depres-
ion has a causal effect on the development of HF or whether
t is a symptom of HF syndrome. However, our results indicate
he need to improve depressive symptoms in HFpEF and HFrEF
atients.
epressive symptoms and clinical outcomes
Interestingly, we found that co-morbid symptoms of depres-
ion are risk factors for adverse cardiac events in HFrEF and HFpEF
atients, and this trend was remarkable in HFrEF. These results
xpand ﬁndings from previous investigations [7–10]. A meta-
nalysis of 8 studies has found that HF patients with heightened
epressive symptoms or depressive disorder had a 2-fold increased
isk of death and associated clinical outcomes [6].  However, most
atients included in the meta-analysis had HFrEF. Our studies
eafﬁrm the importance of co-morbid symptoms of depression
s an independent predictor of prognosis in HFpEF and HFrEF
atients.
Various reasons for this observed increased risk of adverse
linical outcomes and depressive symptoms have been proposed.
epression may  contribute to poor prognosis through adverse
ffects on health behaviors including non-adherence of prescribed
reatment plans [19,22,23].  Several pathophysiologic pathways
ave also been identiﬁed in HFrEF. Depression has been shown
o be related to decreased heart rate variability, blunted barore-
ex sensitivity, heightened sympathetic nervous system activity,
lood hypercoagulability, increased inﬂammation, and endothelial
ysfunction in HFrEF [19,22,23].  Each of these pathways has been
ssociated with poor outcomes and may  act independently or syn-
rgistically to increase risk in HFrEF. Most of these pathways may
e commonly shared in HFpEF, but further studies are necessary to
larify this point.Factors associated with depressive symptoms
The identiﬁcation of HF patients with depressive symptoms
is important because of the association between depression
and adverse outcomes. Knowing the risk factors for depressive
symptoms may  facilitate the treatment. Interestingly, usage of -
blockers was  associated with fewer symptoms of depression in
HFrEF patients. As described above, depression shares a common
pathophysiology with HFrEF [19], i.e. HFrEF is clearly accompa-
nied by high neurohormonal activation, with norepinephrine and
renin–angiotensin–aldosterone. In depression, sympathetic ner-
vous system hyperactivity is associated with overstimulation of
the hypothalamic–pituitary–adrenal (HPA) axis [19,22,23].  In view
of the similarities of these neurohormonal alterations, lipophilic
-blockers such as carvedilol that have been established to be
efﬁcacious in HFrEF could alleviate symptoms of depression by
reducing hyperactivity of the HPA axis by passing thorough the
blood–brain-barrier. In this study, a univariate analysis also showed
that usage of ACEIs and/or ARBs was associated with fewer symp-
toms of depression in HFrEF patients. Taking these observations
into consideration, ACEIs and/or ARBs as well as -blockers may  be
able to confer beneﬁcial effects on HFrEF patients with depressive
symptoms. However, further research is necessary to conﬁrm these
indications. In contrast, we observed no signiﬁcant association of
depressive symptoms with usage of -blockers, ACEIs and/or ARBs
in HFpEF patients, which is similar to ﬁndings that these drugs did
not have a clear impact on clinical outcomes in HFpEF [13].
Being widowed or divorced was  also associated with having
more depressive symptoms in HFrEF patients, which is consis-
tent with a prior study showing that the death of a loved one
worsens depressive symptoms [24]. Emotionally stressful events,
including loss, can trigger pure adrenergic stimulation and
increased circulation of cytokines, such as tumor necrosis factor-
alpha and interleukin-6 [22], and cytokine levels may  also increase
in patients with depression [22]. Because of the high neurohor-
monal activation and the increased levels of cytokines in HFrEF
patients, emotional stress may  facilitate the development of
depressive symptoms in HFrEF patients. Having a spouse is often
an indication of the highest available level of social support, which
has been shown to be an important factor in reducing depressive
symptoms and in improving survival [24,25]. Clarifying the spe-
ciﬁc needs of patients who are widowed or divorced and then
identifying and reinforcing current social support networks could
be helpful in improving depressive symptoms in HFrEF patients.
With respect to HFpEF patients, usage of warfarin was an
independent risk factor for having more depressive symptoms.
Although well-controlled anticoagulation with warfarin could
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otentially prevent the strokes related to atrial ﬁbrillation and heart
alve replacement, the therapeutic range for anticoagulants is nar-
ow [26,27].  To maintain this narrow target range, patients require
requent monitoring and dose adjustment. Numerous barriers to
he use of warfarin have also been reported: regular visits to the
linic, dietary restrictions for foods that contain vitamin K, and
nxiety regarding potential hemorrhagic events and possible drug
nteractions [28,29]. These difﬁculties associated with warfarin
an potentially reduce the quality of life and increase depressive
ymptoms [29]. Meta-analyses have shown that self-testing and
elf-management of oral anticoagulation reduce thromboembolic
vents and improve survival [26,27].  Psychoeducational support
n the patients taking warfarin may  be able to reduce depressive
ymptoms, although it is not feasible for all patients. Regarding
FrEF patients, usage of warfarin was not related to depressive
ymptoms. It may  be because HFrEF patients without warfarin had
epressive symptoms similar to those with warfarin, suggesting
n importance to provide depression treatment and care tailored
o patient’s needs in HFrEF with or without warfarin.
We observed that usage of antidepressants and/or anti-anxiety
rugs was likely to result in more depressive symptoms in HFrEF
nd HFpEF patients. However, because the study was not designed
o assess impacts of the drugs, the signiﬁcance of this observa-
ion is unclear. From previous studies, selective serotonin reuptake
nhibitors seem to be a safer choice for the treatment of depressed
F patients, but the long-term effects on HF prognosis remains
o be conﬁrmed [30]. The recent SADHART-CHF trial that tested
ertraline has not shown any beneﬁcial effect on either cardiovas-
ular or all-cause mortality in HFrEF patients [12]. Thus, the current
ptimal treatment therapy for HF itself and psychoeducational sup-
ort incorporates the fundamental approach of reducing depressive
ymptoms and improving clinical outcomes in HF patients and
epressive symptoms.
tudy limitations
Our study has several potential limitations. First, the clinical
iagnosis of depression cannot be made with CES-D, which has
een shown to be a reliable and valid instrument for measur-
ng depressive symptoms [17,18].  Second, the generalizability of
his study was limited because all patients were recruited from a
ardiovascular outpatient clinic at a single university hospital in
okyo. Third, hemodialysis patients were excluded in this study.
urther study is necessary to evaluate impacts of hemodialysis
n depressive symptoms and clinical outcomes in HF patients.
orth, a cross-sectional assessment of variables including depres-
ive symptoms and usage of -blockers cannot conﬁrm a causative
elationship. Fifth, the small sample size and low frequency of
dverse events in this study limited the number of variables exam-
ned in multivariate analyses and the statistical signiﬁcance of our
ndings. Finally, depressive symptoms were assessed only at base-
ine. Using only one snapshot assessment may  miss the true nature
f these symptoms in a given individual. The relationship between
he change in depressive symptoms and subsequent clinical out-
omes needs to be investigated in future research.
onclusions
This study has revealed that the prevalence of depression is
4% in HFrEF patients and 25% in HFpEF patients, suggesting that
epression is common, irrespective of LVEF. It has also demon-
trated that increased symptoms of depression are associated with
n increased risk of adverse cardiac events, independent of HF
everity in HFrEF and HFpEF patients. To better understand treat-
ent and care for patients with HF and depressive symptoms, we
[iology 60 (2012) 23–30 29
have explored factors associated with these symptoms. Indepen-
dent predictors for experiencing more depressive symptoms are
non-usage of -blockers and being widowed or divorced in the
HFrEF group and usage of warfarin in the HFpEF group. These ﬁnd-
ings suggest that -blocker therapy reduces depressive symptoms
in HFrEF. In contrast, treatment for depression remains to be eluci-
dated in HFpEF.
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